OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
083790$1166.0056

CG Invites Co Ltd

PharmaceuticalsVerified

CG Invites Co Ltd has a market price of 1,166 KRW and a market cap of 89,658,616,212 KRW, with a price-to-book ratio of 0.85 and a price-to-tangible-book ratio of 0.85. The company's liquidity position is characterized by a current ratio of 0.51 and a negative free cash flow of -13,896,914,440 KRW, indicating a medium liquidity risk. The company's debt-to-equity ratio is 0.78, with long-term debt of 82,518,052,690 KRW and total equity of 105,152,742,370 KRW. The company's profitability is negative, with a return on equity of -3.35% and a return on assets of -1.57%. The operating income is -23,746,367,760 KRW, and the net income is -3,520,966,900 KRW. These figures are below the industry median for profitability metrics, indicating a weak performance relative to its peers. CG Invites Co Ltd's revenue is concentrated across three segments: Pharmaceutical Research and Development, Pharmaceutical Manufacturing, and Other. The company's revenue is not disclosed by segment, but the Other segment includes the manufacture and sale of hot packs and other household items. The company's geographic exposure is primarily in Korea, with no significant international operations disclosed. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's revenue history shows a total revenue of 27,391,445,370 KRW, but the operating cash flow is negative at -17,412,712,040 KRW. The capital expenditure is -7,992,704,100 KRW, indicating a reduction in investment. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flags include a negative net cash position after subtracting total debt. The company's dilution potential is low, with no significant dilution sources identified. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.

30-day price · 083790-241.00 (-18.4%)
Low$1050.00High$1398.00Close$1068.00As of22 May, 00:00 UTC
Profile
CompanyCG Invites Co Ltd
Ticker083790.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. CG Invites Co Ltd is a Korea-based company engaged in the development and manufacturing of pharmaceuticals, operating through three segments: Pharmaceutical Research and Development, Pharmaceutical Manufacturing, and Other, which includes the manufacture and sale of hot packs and other household items.

Classification. CG Invites Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a classification confidence of 0.92.

CG Invites Co Ltd has a market price of 1,166 KRW and a market cap of 89,658,616,212 KRW, with a price-to-book ratio of 0.85 and a price-to-tangible-book ratio of 0.85. The company's liquidity position is characterized by a current ratio of 0.51 and a negative free cash flow of -13,896,914,440 KRW, indicating a medium liquidity risk. The company's debt-to-equity ratio is 0.78, with long-term debt of 82,518,052,690 KRW and total equity of 105,152,742,370 KRW. The company's profitability is negative, with a return on equity of -3.35% and a return on assets of -1.57%. The operating income is -23,746,367,760 KRW, and the net income is -3,520,966,900 KRW. These figures are below the industry median for profitability metrics, indicating a weak performance relative to its peers. CG Invites Co Ltd's revenue is concentrated across three segments: Pharmaceutical Research and Development, Pharmaceutical Manufacturing, and Other. The company's revenue is not disclosed by segment, but the Other segment includes the manufacture and sale of hot packs and other household items. The company's geographic exposure is primarily in Korea, with no significant international operations disclosed. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's revenue history shows a total revenue of 27,391,445,370 KRW, but the operating cash flow is negative at -17,412,712,040 KRW. The capital expenditure is -7,992,704,100 KRW, indicating a reduction in investment. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flags include a negative net cash position after subtracting total debt. The company's dilution potential is low, with no significant dilution sources identified. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.
Key takeaways
  • CG Invites Co Ltd has a negative net income and operating income, indicating poor profitability.
  • The company's liquidity position is weak, with a current ratio of 0.51 and a negative free cash flow.
  • The company's debt-to-equity ratio is 0.78, suggesting a moderate level of leverage.
  • The company's return on equity and return on assets are negative, indicating poor asset utilization and equity returns.
  • The company's revenue is concentrated across three segments, with no significant international operations.
  • # RATIONALES
  • margin_outlook_rationale: The company's negative operating income and net income suggest a deteriorating margin outlook driven by poor cost control and revenue generation.
  • rd_outlook_rationale: The company's R&D activities are likely to remain a cost center given the negative operating income and lack of disclosed R&D revenue.
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$27.39B
Gross profit-$1.94B
Operating income-$23.75B
Net income-$3.52B
R&D
SG&A
D&A
SBC
Operating cash flow-$17.41B
CapEx-$7.99B
Free cash flow-$13.90B
Total assets$224.11B
Total liabilities$118.96B
Total equity$105.15B
Cash & equivalents$11.58B
Long-term debt$82.52B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$1166.00
Market cap$89.66B
Enterprise value$160.59B
P/E
Reported non-GAAP P/E
EV/Revenue5.9
EV/Op income
EV/OCF
P/B0.8
P/Tangible book0.8
Tangible book$105.15B
Net cash-$70.93B
Current ratio0.5
Debt/Equity0.8
ROA-1.6%
ROE-3.4%
Cash conversion5.0%
CapEx/Revenue-29.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric083790Activity
Op margin-86.7%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-12.9%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin-7.1%19.7% medp25 19.7% · p75 39.8%bottom quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-29.2%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity78.0%71.3% medp25 19.0% · p75 91.7%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:10 UTC#e518943e
Market quoteclose KRW 1166.00 · shares 0.08B diluted
no public URL
2026-05-10 06:10 UTC#77870b7a
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:12 UTCJob: d7e738a8